Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period by Sowers, MaryFran R. et al.
Ann. N.Y. Acad. Sci. ISSN 0077-8923
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Issue: Reproductive Aging
Relating smoking, obesity, insulin resistance, and ovarian
biomarker changes to the final menstrual period
MaryFran R. Sowers,1,2 Daniel McConnell,1 Matheos Yosef,1 Mary L. Jannausch,1
Sioban D. Harlow,1 and John F. Randolph, Jr.2
1Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan. 2Department of
Obstetrics and Gynecology, University of Michigan Health Sciences System, Ann Arbor, Michigan
Address for correspondence: MaryFran Sowers, Ph.D., Department of Epidemiology, School of Public Health, University of
Michigan, 1415 Washington Heights, Rm 1846, Ann Arbor, Michigan 48109. mfsowers@umich.edu
To determine if smoking, obesity, and insulin resistance mediated age at final menstrual period (FMP), we examined
anti-Müllerian hormone (AMH), inhibin B, and follicle-stimulating hormone (FSH) as biomarkers of changing
follicle status and ovarian aging. We performed a longitudinal data analysis from a cohort of premenopausal women
followed to their FMP. Our results found that smokers had an earlier age at FMP (P < 0.003) and a more rapid decline
in their AMH slope relative to age at FMP (P < 0.002). Smokers had a lower baseline inhibin B level relative to age
at the FMP than nonsmokers (P = 0.002). Increasing insulin resistance was associated with a shorter time to FMP
(P < 0.003) and associations of obesity and time to FMP were observed (P = 0.004, in model with FSH). Change in
ovarian biomarkers did not mediate the time to FMP. We found that smoking was associated with age at FMP and
modified associations of AMH and inhibin B with age at FMP. Insulin resistance was associated with shorter time to
FMP independent of the biomarkers. Interventions targeting smoking and insulin resistance could curtail the undue
advancement of reproductive aging.
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Introduction
Epidemiological studies have reported that cigarette
smoking leads to reduced ovarian function and fer-
tility and an earlier age at menopause,1 and both
body size and insulin resistance have been vari-
ably associated with measures of ovarian function.2
The degree to which environmental factors, such as
smoking, obesity, and insulin resistance, may impact
follicle number and quality is an important ques-
tion as the nature and quantity of ovarian reserve
is indicative of reproductive capacity and the time
remaining during which conception can occur prior
to the menopause. Increasing evidence suggests that
measured anti-Müllerian hormone (AMH) and in-
hibin B in conjunction with follicle-stimulating hor-
mone (FSH) could reflect the shrinking ovarian
reserve over time and provide a useful means
of investigating the impact of environmental
factors.
In women, AMH (Müllerian Inhibiting Sub-
stance [MIS]) from the granulosa cells of ovarian
follicles reflects the transition of resting primor-
dial follicles into growing primary and secondary
follicles and the subsequent recruitment of FSH-
sensitive follicles in the early antral stage.3–5 Because
AMH is produced only in growing ovarian follicles,
serum AMH levels are regarded as a direct indica-
tor of ovarian reserve, representing the quantity and
quality of the recruitable ovarian follicle pool.6 We
have identified a linear decline of logAMH to low or
nondetectable levels 5 years prior to the natural final
menstrual period (FMP).7
Inhibin B is the primary inhibin produced by
the small antral follicles; its levels have been in-
terpreted as indicating growth of the antral folli-
cle cohort.8 Produced by granulosa cells, inhibin
B suppresses FSH secretion through direct nega-
tive feedback to the pituitary.9−11 There is a curvi-
linear decline of follicular-phase loginhibin B to
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undetectable levels 4–5 years prior to the natural
FMP.7
Reproductive aging is also characterized by a
progressive rise in serum FSH levels and reduced
levels of ovarian steroids.12–14 This FSH rise, a cen-
tral endocrine feature of the perimenopause, was
described by Sherman and Korenman in 1975,15 and
has been confirmed in subsequent epidemiological
studies of the menopausal transition.16–18 Globally,
the FSH rise is associated with a progressive loss of
ovulatory function.19
The degree to which environmental factors, such
as smoking, obesity, and insulin resistance, impact
the association of these ovarian markers in their re-
lation to time to FMP and age at FMP is the subject
of this research. The goal was to determine if smok-
ing behavior, obesity, and HOMA-IR, an indicator
of insulin resistance among nondiabetics, were as-
sociated with time to FMP independent of age and
age at FMP. Further, we evaluated if women who
smoked or were more insulin resistant had different
AMH, inhibin B, and FSH profiles assuming that
these biomarkers reflected ovarian aging.
Methods and procedures
Population
This report is based on data from 50 Michigan Bone
Health and Metabolism study (MBHMS) enrollees
of a possible 629 women. The women were pre-
and early perimenopausal at their baseline evalu-
ation. Archival serum specimens from the initial
six consecutive annual visits were assayed for AMH,
inhibin B, and FSH. In addition, archival informa-
tion from physical measurements and interviews
were used to identify obesity and smoking behavior
at these visits. MBHMS enrollees were followed an-
nually, allowing the subsequent documentation of
their FMP.
The organization of the population-based
MBHMS cohort has been described.20 It was or-
ganized in 1992 from two sampling sources in-
cluding a list of the female offspring, aged 24–
44 years, from the community-based Tecumseh
(Michigan) Community Health Study (TCHS) en-
rollees and Kohl’s Directory, a listing of community
female residents (also aged 24–44) whose parents
had not participated in the TCHS. This report in-
cludes data collected during the 15-year period from
1992/1993 through 2006/2007, excluding the 18-
and 14-month lapses in funding in 1997 and 2003,
respectively. Written informed consent has been ob-
tained from all participants; this study has been ap-
proved by the University of Michigan Institutional
Review Board. Since study inception, the annual co-
hort visits have included interviews about health sta-
tus, menstrual bleeding patterns and health-related
behaviors, and phlebotomy to provide serum and
urine specimens for assay of hormones, metabolic
measures, and repository storage.
To develop this substudy, which has been re-
ported,7 we selected and assayed repository spec-
imens to correspond in time to 6 yearly measures,
beginning in 1993, when regularly cycling (nine or
more menstrual cycles per year) women were in
their pre- and early menopause stages. This was to
assure that we could examine both level and rate
of change in the ovarian markers as women en-
tered the menopause transition. Therefore, women
were eligible for inclusion in this substudy only if
their FSH values in 1992/1993 or 1993/1994 were
≤14 mIU/mL. Then, women were selected for study
if they had a naturally occurring FMP by the 2006
annual visit (within the 13-year period after the
baseline) and if their age at FMP was more than
41 years and therefore not reflective of factors
thought to contribute to premature ovarian ag-
ing. Further, these women had no exposure to hor-
mone therapy use or gynecological surgeries dur-
ing the 13-year study period. It was important to
be able to examine rates of change in the ovarian
markers to address our hypotheses that smoking,
insulin resistance and obesity altered ovarian ag-
ing and were thereby associated with menopause
characteristics.
Data from 50 women meeting these eligibility cri-
teria were selected. They were, on average, 4 years
older than women not selected (a mean 1992 base-
line age of 41 [SD = 2.6] years versus 38 years
[SD = 5.0]). Initial body mass index (BMI), insulin
resistance index, and smoking frequency were not
statistically significantly different in selected versus
nonselected women.
Specimens and assays
Specimens were collected fasting in days 2–7
of the follicular phase of the menstrual cycle,
aliquoted and stored at –80◦ C without thaw un-
til assay. A commercially available enzyme-linked
immunosorbent assay (ELISA) from Diagnos-
tic Systems Laboratories (Beckman Coulter, DSL,
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Webster, TX) was used for the in vitro quan-
titative measurement of Müllerian Inhibiting
Substance/Anti-Müllerian Hormone in human
serum. This ELISA is a direct competitive im-
munoassay without sample extraction or hydrol-
ysis. The detection system consisted of a biotiny-
lated secondary antibody and streptavidin-labeled
horseradish peroxidase. Samples were assayed in
duplicate. There is no detectable cross-reactivity
with closely related compounds. The assay mea-
sured AMH concentrations ranging from 0.017 to
10 ng/mL with an assay range (standard curve)
of 0.05 to 10 ng/mL. Manufacturer-specified in-
terassay coefficients of variation (CV) were 8.0% at
0.15 ng/mL, 4.8% at 0.85 ng/mL, and 6.7% at 4.28
ng/mL (mean = 6.5%); intra-assay CVs were 4.6%
at 0.14 ng/mL, 2.4% at 0.84 ng/mL, and 3.3% at
4.41 ng/mL (mean = 4.0%). The level of assay de-
tection was 0.05 ng/mL.
Serum inhibin B concentrations were measured
in duplicate with an -ßB dimeric ELISA (DSL-10–
84100, Diagnostic Systems Laboratories) and refer-
enced to a standard of human inhibin B preparation
isolated from human follicular fluid provided by
Nigel Groome (Oxford Brookes University, Oxford,
UK). The within- and between-assay variations were
11.7% and 15.6%, respectively. The assay lower
limit of detection (lowest standard curve point) was
10.0 pg/mL. Assays for both AMH and inhibin B
were measured in a single time period and kits came
from single lots.
FSH concentrations were measured in annual
batches across time using an in-house (CLASS lab-
oratory, University of Michigan) two-site chemi-
luminoscence immunoassay directed to different
regions on the beta subunit.21 It has an interas-
say CV of 12.0% and 6.0% and a lower limit of
detection of 1.05 mIU/mL. The intra-assay CV at
five locations along the standard curve were as fol-
lows: 7.8% (3.3 mIU/mL), 3.2% (9.9 mIU/mL),
5.1% (18.2 mIU/mL), 4.4% (22 mIU/mL), and 3.3%
(60.8 mIU/mL).
Serum insulin was measured using Radioim-
muneassay (DPC Coat-a-count, Los Angeles,
CA). Glucose was measured with a hexokinase-
coupled reaction on a Hitachi 747–200 (Boehringer
Mannheim Diagnostics, Indianapolis, IN). The
hemostatic model-based insulin resistance index
(HOMA-IR) was calculated as ([fasting insulin ×
fasting glucose]/22.5).22 Serum glucose and insulin
values were not available from the 1992/1993 as-
sessment, but available at the subsequent five data
points. HOMA-IR was treated as a time-varying
covariate.
Other measures
Height (cm) and weight (kg) were measured at an-
nual study visits with a calibrated stadiometer and
balance-beam scale and these data used to calcu-
late BMI as weight (in kilograms) divided by the
square of height (in meters). Obesity was defined
by dichotomizing BMI at 30 kg/m2. Smoking status
at study entry was included as an ever versus never
dichotomous variable.
Statistical analysis
Variable distributions were examined for normality,
the presence of nonplausible outliers, and/or chang-
ing variability over time. Scatter plots and box plots
were used to determine whether transformations
of outcome measures were necessary for satisfying
model assumptions.
Biomarkers (logAMH, loginhibin B, and logFSH
levels) as independent variables were related to time
to FMP and to age at FMP as the outcomes of inter-
est. First, the six annual biomarker values for each
woman were decomposed into subject-specific in-
tercept and slope. Then, these were incorporated as
random independent variables and related to the
outcome measure, age at FMP. When values below
assay detection were present (for the biomarkers
AMH and inhibin B), we used the nonlinear mixed
model procedure, Proc NLMixed (in SAS) to address
those below-detection values as in Thiébaut and
Jacqmin-Gadda.23 Otherwise, modeling was under-
taken using Generalized Estimating Equations.
Baseline variables for age, smoking, or BMI were
added to the basic models as independent main ef-
fects. In addition, and in separate models, HOMA-
IR was treated as a continuous, time-varying co-
variate. Then, interaction terms were included in
the models to test the hypotheses that in women
who smoked, were obese or insulin resistant, these
environmental factors modified the relationships of
the measured biomarkers with FMP.
Appropriateness of model fitting was assessed
both graphically and using residual analyses. SAS
9.1 and Macro facilities (SAS Institute, Cary, NC)
were used to perform the statistical analyses.
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Results
The baseline hormone biomarker characteristics
of the 50 women included mean (SD) AMH of
0.66 ± 0.50 ng/mL; mean (SD) inhibin B of
72 ± 44 pg/mL; and mean (SD) FSH of 8.0 ±
2.4 mIU/mL. Table 1 shows the biomarker values
across the six time points and the number of values
that were below the AMH and inhibin B assay detec-
tions. The profiles of AMH and inhibin B changed
significantly over the 6-year interval (P < 0.0001,
respectively). Increasingly over time, the propor-
tion of values below the levels of assay detection
increased (P < 0.0001, respectively). The change
in AMH and inhibin B profiles predated the rise
in the follicular-phase FSH profile. The mean
age in 1993 of the 50 women was 41.5 years and
the mean (SD) BMI was 27.0 ± 5.9 kg/m2. Twenty-
four percent of women were obese and 18% of
women smoked at baseline. Mean age at FMP was
51 years.
Age at FMP, smoking, and ovarian biomarkers
As seen in Table 2, there were statistically signifi-
cant and important associations between the ovar-
ian markers and age at FMP, but the nature of the
association varied according to smoking status. The
rate of change of AMH is related to age at FMP.
However, women who smoked were likely to have
an earlier age at FMP and the slope of their AMH
levels in relation to age at FMP was steeper (that is,
AMH levels declined faster in women who smoked,
which was, in turn, associated with an earlier age
at FMP). As seen in the second model of Table 2,
smoking was associated with an earlier age at FMP
and smoking modified the level at which inhibin
B was associated with the earlier age at menopause
in that it happened at a higher level of baseline in-
hibin B (P = 0.002). Obesity and HOMA-IR were
not associated with age at FMP. FSH not associ-
ated with age at FMP and there was no interac-
tion between FSH and smoking in relation to age
at FMP.
Time to FMP, AMH, and lifestyle modifiers
logAMH was significantly associated with time to
FMP, with a decline of one unit in observed logAMH
being associated with 1.75 earlier years to FMP
(P < 0.0001). When AMH became nondetectable,
it was also significantly associated with time to FMP.
An increasingly higher HOMA-IR was significantly
associated with a closer time to FMP (P = 0.009),
apart from AMH. However, neither baseline smok-
ing nor obesity measures were significantly associ-
ated with time to FMP (see Table 3). There were no
statistically significant interactions between AMH
and smoking, obesity, or HOMA-IR in relation to
time to FMP, indicating that the relationship be-
tween AMH and the time to FMP was not sig-
nificantly different in women who smoked, were
obese, or had greater insulin resistance (models not
shown).
Table 1. Sample characteristics from 50 pre- and perimenopausal women at six points across time—MBHMS
1993/1994 1994/1995 1995/1996 1997/1998 1998/1999 1999/2000
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age 41.5 ± 2.67 42.5 ± 2.67 43.4 ± 2.61 46.3 ± 2.60 47.3 ± 2.67 48.3 ± 2.56
AMH (ng/mL)
Observed valuesa 0.66 ± 0.50 0.51 ± 0.36 0.39 ± 0.30 0.16 ± 0.11 0.19 ± 0.11 0.15 ± 0.10
% ↓ detection 3 (6%) 5 (10%) 8 (16%) 26 (52%) 27 (54%) 32 (64%)
Inhibin B (pg/mL)
Observed valuesa 72 ± 44 56 ± 43.5 59 ± 35 38 ± 21 47 ± 72 34 ± 30
% ↓ detection 2 (4%) 2 (4%) 9 (18%) 18 (36%) 23 (46%) 23 (46%)
FSH (mIU/mL) 8.0 ± 2.4 7.6 ± 3.7 7.7 ± 4.9 16.4 ± 15.7 18.3 ± 15.2 21.5 ± 18.3
HOMA-IR N/Ab 1.68 ± 1.05 1.84 ± 1.74 2.48 ± 2.36 2.35 ± 2.10 2.60 ± 2.97
BMI (kg/m2) 27.0 ± 5.9 27.6 ± 6.1 27.6 ± 5.9 28.3 ± 6.5 28.5 ± 6.3 28.8 ± 6.4
aData are for AMH and inhibin B that are observed above level of assay detection.
bHOMA-IR data are not available from this annual visit.
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Table 2. Association of age at final menstrual period with logAMH and loginhibin B profiles according to smoking
status
Covariates Beta ± SE P-value
Model of AMH and smoking
logAMH intercept 0.12 ± 0.39 0.76
logAMH slope 11.49 ± 4.14 0.008
Smoked at baseline −7.31 ± 2.36 0.003
logAMHintcpt∗smoking at baseline 1.92 ± 0.65 0.005
logAMHslope∗smoking at baseline −19.27 ± 5.84 0.002
Model of inhibin B and smoking
logInhibin B intercept −2.75 ± 2.19 0.22
logInhibin B slope 3.92 ± 4.02 0.33
Smoked at baseline −44.32 ± 12.69 0.001
logInhibin B intcpt∗smoking at baseline 10.20 ± 3.12 0.002
logInhibin B slope∗smoking at baseline −7.99 ± 6.23 0.21
Bolded variables are statistically significant.
Time to FMP, loginhibin B, and lifestyle
modifiers
A decline of one unit in observed loginhibin B was
associated with 1.58 earlier years to FMP. Inhibin
B below detection was also associated with time to
FMP. As seen in Table 4, insulin resistance, expressed
with HOMA-IR, was significantly independently as-
sociated with time to FMP (P = 0.003); the asso-
ciation with obesity, defined as a BMI >30 kg/m2,
was of borderline statistical significance (P = 0.06).
Women who smoked did not have a statistically
different time to FMP than women who did not
smoke. There were no statistically significant inter-
actions with smoking behavior, obesity classifica-
tion, or HOMA-IR and inhibin B in relation to time
to FMP (data not shown).
Time to FMP and FSH
Though the linear component of logFSH was not
associated with time to the FMP (P = 0.13), the
curvilinear rate of change in logFSH was associated
with the time to the FMP (P = 0.0005). As reported
in Table 5, smoking was not associated with time
to FMP (P = 0.46). In addition to the curvilinear
rise in FSH, obesity (P = 0.004) and HOMA-IR
(P = 0.0003) were independently associated with
time to FMP in separate models. There were no
significant interactions with smoking, obesity, or
HOMA-IR and FSH in relation to time to FMP (data
not shown).
Discussion
The ovarian aging concept incorporates the tim-
ing of reproductive events, including the beginning
of subfertility, the transition from menstrual cycle
regularity to irregularity, absolute infertility, and the
final menstrual period.24 Identifying lifestyle factors
that influence the rate of ovarian aging is of interest,
both clinically and from a public health perspective.
After including 6-year levels and changes in AMH,
inhibin B, and FSH as biomarkers of the progressive
decline in functional ovarian cells, we considered
whether three factors, smoking, obesity, and insulin
resistance, might be associated with the rate of ovar-
ian aging in their relation to both age at FMP and
time to FMP independent of age.
Role of smoking
We identified a marked difference between smok-
ers and nonsmokers in the relation of both baseline
logAMH and change in logAMH with age at FMP.
There was an earlier age at FMP and a more rapid
decline in AMH levels among women who were
smokers, suggesting that smoking behavior may lead
to either fewer oocytes or an earlier decline in oocyte
number. In addition, we found that smoking was as-
sociated with a lower initial level of inhibin B but not
associated with the rate of change in inhibin B levels.
This led us to conclude that smoking might be asso-
ciated with an earlier onset of processes associated
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Table 3.The associations of time to FMP and AMH incorporating smoking, obesity (defined at baseline), or HOMA-IR
(time-varying) as main effects
Beta ± SE P-value
Model of AMH and smoking
logobserved AMH −1.75 ± 0.14 <0.0001
AMH below detection 6.57 ± 0.31 <0.0001
Smoked at baseline (dummy variable) −0.22 ± 0.38 0.57
Model of AMH and obesity (dichotomized)
logobserved AMH −1.75 ± 0.14 <0.0001
AMH below detection 6.57 ± 0.32 <0.0001
Obesity > 30 kg/m2 0.03 ± 0.44 0.94
Model of AMH with time-varying HOMA-IR
logobserved AMH −1.65 ± 0.16 <0.0001
AMH below detection 6.06 ± 0.36 <0.0001
HOMA-IR (time-varying) 0.16 ± 0.06 0.009
Bolded variables are statistically significant. Smokers were designated 1 while nonsmokers were designated with 0.
with ovarian aging, but not necessarily a disruption
in the sequence of activities and that inhibin B and
FSH are better indicators of the sequence of activ-
ities leading to the selection of a dominant follicle
as compared to being indicators of the size of the
follicle pool.
Multiple epidemiological studies have reported
that cigarette smoking leads to reduced ovar-
ian function and fertility and an earlier age at
menopause,25 suggesting that smoking impairs
ovarian function. The mechanism of tobacco’s toxic
effect on the ovary is unclear but may be due to
effects on oocyte quantity,26 oocyte quality, or dis-
ruption of endocrine function.27,28 Cotinine, a long-
lived metabolite of nicotine, can be detected in
ovarian follicular fluid, indicating that toxic con-
stituents of cigarette smoke including nicotine and
cadmium have access to the follicular environment
and could affect ovarian function.29–32
The sample size of this report, limited to data
from 50 women, precluded our investigation of
important related public health questions, such as
whether quitting smoking altered these associations
and whether the patterns varied according to the
time of initiation, duration, or total exposure to
tobacco use.
Role of obesity and HOMA-IR
We identified that there were stronger and more
frequent associations of insulin resistance with the
biomarkers of ovarian aging or their change with
time than with obesity when using a widely used
cutpoint for obesity (or with BMI treated as a con-
tinuous variable, data not reported). Data on the
association of AMH and obesity are scarce. A recent
study reported that AMH levels were significantly
lower in obese women as compared to nonobese
women in the late reproductive years; however, that
study did not report measures of insulin resistance.33
There are reports of an inverse association of obe-
sity with inhibin B levels in women with polycystic
ovary syndrome (PCOS) and in anovulatory pre-
menopausal women.34,35 Thus, there is limited data
in healthy reproductively aged women suggesting a
significant association between decreasing inhibin
B levels and greater BMI but mechanisms for the
association have not been established.36
We identified that AMH and insulin resistance
were predictive of time to FMP. Importantly, obe-
sity and insulin resistance should not be treated as
synonymous as there are obese women without in-
sulin resistance and lean insulin resistant women.37
Published studies of insulin resistance and ovarian
biomarkers are largely limited to investigations of
PCOS.38 Several studies in women with PCOS have
identified that elevated circulating levels of AMH are
correlated with increased numbers of small antral
follicles in the ovary,39 potentially reflecting alter-
ations granulosa cell function and a role not nec-
essarily associated with body size.40,41 If insulin
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Table 4. The associations of time to FMP with loginhibin B incorporating smoking, obesity (defined at baseline), or
HOMA-IR (time-varying) as main effects
Covariates Beta ± SE P-value
Model of inhibin B with smoking
logInhibin B −1.58 ± 0.28 <0.0001
Inhibin B below assay detection −2.52 ± 1.08 0.02
Smoked at baseline 0.33 ± 1.81 0.86
Model of inhibin B with obesity
logInhibin B −1.58 ± 0.22 <0.0001
Inhibin B below detection −2.43 ± 0.88 0.0065
Obesity > 30 kg/m2 0.77 ± 0.41 0.06
Model of inhibin B with time-varying HOMA-IR
logInhibin B −1.27 ± 0.24 <0.0001
Inhibin B below detection −1.81 ± 0.92 0.052
HOMA-IR (time-varying) 0.22 ± 0.07 0.003
Bolded variables are statistically significant.
resistance has an impact on granulosa or theca cell
functioning, this would be consistent with our find-
ings. As the perception of PCOS changes from that
of a reproductive disorder to one of a metabolic syn-
drome with reproductive implications, greater focus
is being placed on dysfunction of the hypothalamic–
pituitary axis and primary defects of insulin activity
as contributory causes to the syndrome.42 Although
the underlying cause of the ovulatory dysfunction
associated with PCOS is unknown, it is thought
to be associated with the dysregulation of thecal
steroidogenesis.43 The resulting hyperandrogenism
plays a role in the arrest of folliculogenesis,44,45 a
mechanism that has not been evaluated in nor-
mal ovarian aging. Alternatively, studies in knock-
out models suggest considering other mechanisms
including insulin receptor insufficiency or GLUT4
dysregulation.46
This report includes strengths and limitations.
The data reflect appropriately collected speci-
mens without thaw-refreeze prior to assay. Data
were obtained from a substudy nested in a
population-based study that includes documenta-
tion of the natural progression of women through
stages of the menopause transition to the FMP and
subsequent postmenopause. This allowed the selec-
tion of archival specimens for assay that represented
the late reproductive period. Simultaneously, infor-
mation about smoking behavior, obesity status, and
insulin resistance were obtained concurrently with
the specimens assayed for AMH, inhibin B, and
FSH and did not require women to engage in inter-
views that required long-term recall. The study de-
sign allowed us to consider change in biomarkers of
ovarian aging and how environmental factors were
related to these changes in relation to menopause
characteristics. However, this is an epidemiological
study without access to certain measures of follicle
status, such as antral follicle count. The population
is Caucasian so findings may not be generalizable
to non-Caucasian women, although the study ad-
dresses factors that are often disproportionately as-
sociated with non-Caucasian populations including
smoking, insulin resistance, and obesity. The major
deficit is that the size of the sample evaluated may be
too small to detect important interactions in relation
to the biomarkers and time to FMP. The sample size
was too limited to detect three-way interaction pat-
terns (insulin resistance in smokers who were obese
versus insulin resistance in smokers who were not
obese) that may characterize important subgroups
that could be targeted for intervention.
In summary, smoking was not only associated
with age at FMP but also modified the associations
of two biomarkers, AMH and inhibin B, with age at
FMP. These biochemical markers for oocyte quality
and quantity may provide an indication of the po-
tential mechanisms whereby smoking is associated
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Table 5. The associations of time to FMP with logFSH and considering smoking, obesity (defined at baseline), or
HOMA-IR (time-varying) as main effects
Covariates Beta ± SE P-value
Model of FSH with smoking
logFSH −1.61 ± 1.05 0.13
logFSH ∗ logFSH 0.72 ± 0.20 0.0005
Smoked at baseline −0.29 ± 0.40 0.46
Model of FSH with obesity (dichotomized)
logFSH −1.62 ± 1.04 0.12
logFSH ∗ logFSH 0.73 ± 0.20 0.0004
Obesity (dichotomized) at baseline 1.22 ± 0.42 0.004
Model of FSH with time-varying HOMA-IR
logFSH −0.37 ± 0.99 0.71
logFSH ∗ logFSH 0.43 ± 0.19 0.03
HOMA-IR (time-varying) 0.27 ± 0.07 0.0003
Bolded variables are statistically significant.
with the earlier age at FMP, but does not necessarily
disrupt progression in the timing of events leading
to the FMP. The absence of significant interactions
between insulin resistance with AMH and inhibin B
in relation to time to FMP may indicate that other
mechanisms in ovarian and adrenal steroidogenesis
should be considered that are not limited to antral
follicle recruitment. Although future studies will
more fully reveal these relationships, both smok-
ing behavior and greater insulin resistance are likely
to accelerate reproductive aging. This report con-
tributes additional evidence that targeting smoking
and insulin resistance would be important practices
to moderate in women as they appear to generate
undue advancement in reproductive aging.
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